Introduction
leukotrienes and prostaglandins [9] . Degranulation of polymorphonuclear leukocytes (PMN ) occurs during extracorporeal circulation. In Inhibition of PMN degranulation by newly patients undergoing regular haemodialysis treatment described proteins PMN degranulation has been used as one of several markers for membrane bioincompatibility [1] . In the Two degranulation inhibiting proteins identical to angiopast, it has been thought that the release of components genin [10] and complement factor D [11] have been from PMN granules follows the activation of the isolated from the ultrafiltrates of end-stage renal discomplement system in a time and membrane material ease patients undergoing regular haemodialysis treatdependent manner. It became clear, however, that ment using high-flux dialysers. Both proteins inhibit in complement activation and PMN degranulation vitro dose-dependently the release of lactoferrin and observed during haemodialysis therapy are independ-metalloproteinases such as collagenase and gelatinase ent activation processes [1, 2] . Cheung et al. [3] per-from PMN [10, 11] . Therefore we asked ourselves: formed in vitro dialysis treatments in the presence of normal and very low-dose heparinization. Low-dose (i) Are plasma levels of the degranulation-inhibiting heparinization caused partial clotting within the filter, proteins elevated in end-stage renal disease resulting in significant complement activation compatients? pared to standard heparinization. The release of lacto-(ii) Are plasma levels of these proteins affected by ferrin from PMN during these procedures, however, high-flux haemodialyser therapy and/or haemowas identical with both anticoagulation modalities. diafiltration? Complement activation depends not only on the type (iii) Is degranulation of PMN inhibited not only in of dialyser but also on whether it is new or reused.
vitro by these PMN degranulation inhibiting proDialyser reuse causes attenuation of complement teins but also in vivo? activation; PMN lactoferrin or myeloperoxidase Recent studies have shown that plasma angiogenin release, however, is not affected by reuse [4] .
[12] and complement factor D [13] levels are markedly elevated in end-stage renal disease patients (up to 15-fold ) as compared to healthy subjects.
What are the intracellular signals for PMN
Haemodialysis treatment with high-flux membranes or degranulation during haemodialysis?
haemodiafiltration causes a decrease of angiogenin and complement factor D via convection, and particularly Intracellular calcium was suggested as a potential via adsorption. Plasma lactoferrin levels were markedly mediator of PMN degranulation. It has been shown higher during haemodialysis with low-flux cellulose that the release of components from neutrophil gran-triacetate or polysulphone dialysis than with the highules was reduced by pretreatment of haemodialysis flux versions of these dialysers, either with the haemopatients with calcium-channel blockers [5] . Inhibition dialysis or haemodiafiltration mode of treatment. Lowof PMN degranulation by calcium-channel blockers flux cellulose triacetate or polysulphone dialysers do was also observed during cardiopulmonary bypass [6 ] . not reduce plasma angiogenin levels, in contrast to the The concept of the role of intracellular calcium trig-high-flux versions. These data clearly show that high gering PMN degranulation was further confirmed by angiogenin and/or complement factor D levels of two studies depleting intracellular calcium of PMN chronically uraemic patients protect against lactoferrin during extracorporeal circulation by citrate. This mode release from PMN during extracorporeal circulation. of anticoagulation abolished lactoferrin [7] or myelop-These data also demonstrate that endogenous PMN eroxidase [8] release from PMN during haemodialysis inhibitors have to be considered if neutrophil activation treatment. In addition to calcium, other cytogenic parameters were measured in order to investigate bioincompatibility of dialyser membrane materials. 
